Evidence map›Paper›PMID 34101496›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).

Maarten C C M Hulshof, Elisabeth D Geijsen, Tom Rozema, Vera Oppedijk, Jeroen Buijsen, Karen J Neelis, Joost J M E Nuyttens, Maurice J C van der Sangen, Paul M Jeene, Jannie G Reinders and 5 more

4 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 167 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 8 pooled it
45.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06173986 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase I/II Multicenter Study Evaluating the Efficacy and Safety of Induction Immunochemotherapy Followed by Concurrent Immuno-Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Cancer(SCR-ESCC-02)

TypeinterventionalSponsorShanghai Chest HospitalRan2023 to 2027Enrolled50ConditionsEsophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal CancerArmsPD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy
NCT06281886 phase2completednot on this mapstarted 2024, after this paper: background citation

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2024 to 2026Enrolled170ConditionsEsophageal Squamous Cell Carcinoma, Efficacy, ToxicityArmsInduction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy, Apatinib, Capecitabine
NCT06912074 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Comparing Hypofractionated Concurrent Chemoradiotherapy Versus Conventional Fractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Open-Label, Randomized Phase II Clinical Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2025 to 2029Enrolled134ConditionsEsophageal Squamous Cell Carcinoma (ESCC)ArmsInduction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurrent Chemotherapy
NCT07086469 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Prospective, Single-arm, Phase II Clinical Trial of Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorSun Yat-sen UniversityRan2025 to 2029Enrolled69ConditionsToripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, ChemoradiotherapyArmsNeoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy, Radiotherapy
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 8 syntheses or guidelines pooled it, 288 citations in OpenAlex.

  1. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Dose escalation based onRadiation oncology (London, England) · 2022
    Trial
  18. Trial
  19. Trial
  20. Trial

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Maarten C C M HulshofDepartment of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0000-0001-5240-3467
Elisabeth D GeijsenDepartment of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands.
Tom RozemaVerbeeten Institute, Tilburg, the Netherlands.
Vera OppedijkRadiotherapeutisch Instituut Friesland, Leeuwarden, the Netherlands.
Jeroen BuijsenDepartment of Radiation Oncology, School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.ORCID 0000-0001-9521-8587
Karen J NeelisLeids Universitair Medisch Centrum, Leiden, the Netherlands.
Joost J M E NuyttensDepartment of Radiotherapy, Erasmus MC, Rotterdam, the Netherlands.
Maurice J C van der SangenDepartment of Radiotherapy, Catharina Ziekenhuis, Eindhoven, the Netherlands.ORCID 0000-0003-1866-7367
Paul M JeeneRadiotherapiegroep, Deventer, the Netherlands.
Jannie G ReindersDepartment of Radiotherapy, Zeeuws Radiotherapeutisch Instituut, Vlissingen, the Netherlands.
Mark I van Berge HenegouwenDepartment of Surgery, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0000-0001-8689-3134
Adriana ThanoDepartment of Biostatistic, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jeanin E van HooftDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.
Hanneke W M van LaarhovenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0000-0003-3546-9709
Ate van der GaastDepartment of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.
Amsterdam University Medical Centers · NLErasmus MC · NLRadiotherapeutisch Instituut Friesland · NLInstituut Verbeeten · NLLeiden University Medical Center · NLMaastricht University · NLRadboud University Nijmegen · NLRadiotherapiegroep · NLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo analyze the effect of radiation dose escalation to the primary tumor on local tumor control in definitive chemoradiation (dCRT) for patients with esophageal cancer. PATIENTS AND

methodsPatients with medically inoperable and/or irresectable esophageal carcinoma, referred for dCRT, were randomly assigned between a standard dose (SD) of 50.4 Gy/1.8 Gy for 5.5 weeks to the tumor and regional lymph nodes and a high dose (HD) up to a total dose of 61.6 Gy to the primary tumor. Chemotherapy consisted of courses of concurrent carboplatin (area under the curve 2) and paclitaxel (50 mg/m

resultsBetween September 2012 and June 2018, 260 patients were included. Squamous cell carcinoma (SCC) was present in 61% of patients, and 39% had adenocarcinoma (AC). Radiation treatment was completed by 94%, and 85% had at least five courses of chemotherapy. The median follow-up time for all patients was 50 months. The 3-year local progression-free survival (LPFS) was 70% in the SD arm versus 73% in the HD arm (not significant). The LPFS for SCC and AC was 75% versus 79% and 61% versus 61% for SD and HD, respectively (not significant). The 3-year locoregional progression-free survival was 52% and 59% for the SD and HD arms, respectively (

conclusionIn dCRT for esophageal cancer, radiation dose escalation up to 61.6 Gy to the primary tumor did not result in a significant increase in local control over 50.4 Gy. The absence of a dose effect was observed in both AC and SCC.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemoradiotherapyDose-Response Relationship, RadiationEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleFollow-Up StudiesHumansMaleMiddle AgedPaclitaxelCarboplatinPaclitaxel

Identifiers

PMID34101496
OpenAlexW3166655131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.